Prader-Willi Syndrome
-
Vanderbilt-developed obesity treatments will be advanced through collaboration with Soleno Therapeutics
A new partnership between Vanderbilt University’s Warren Center for Neuroscience Drug Discovery and clinical stage biopharmaceutical company Soleno Therapeutics will further research into new clinical treatments for multiple obesity syndromes. Read MoreFeb 25, 2021
-
Children’s Hospital opens comprehensive Prader-Willi syndrome clinic
A comprehensive, multidisciplinary clinic serving patients with Prader-Willi syndrome recently opened at Monroe Carell Jr. Children’s Hospital at Vanderbilt. Prader-Willi syndrome (PWS) is a complex genetic disorder that affects appetite, growth, metabolism, cognitive function and behavior. It is characterized by the inability to achieve satiety, developmental delays and intellectual disability,… Read MoreJan 8, 2018
-
Discovery sheds new light on Angelman, Prader-Willi syndromes
A mutation associated with epilepsy and autism also is responsible for a “pale eye” trait in two rare genetic disorders, Angelman syndrome and Prader-Willi syndrome, neuroscientists at Vanderbilt University Medical Center reported this week. Read MoreDec 22, 2016
-
Growth hormone for Prader-Willi
Children with Prader-Willi Syndrome who received growth hormone treatment had cognitive advantages compared to untreated patients. Read MoreAug 25, 2016